Evaluation of the safety, tolerability and pharmacokinetics of ALN-RSV01, a novel RNAi antiviral therapeutic directed against respiratory syncytial virus (RSV). - Wikidata - wikimedia - TriplyDB

Evaluation of the safety, tolerability and pharmacokinetics of ALN-RSV01, a novel RNAi antiviral therapeutic directed against respiratory syncytial virus (RSV).

Evaluation of the safety, tolerability and pharmacokinetics of ALN-RSV01, a novel RNAi antiviral therapeutic directed against respiratory syncytial virus (RSV).

http://www.wikidata.org/entity/Q45397417

about

siRNA Versus miRNA as Therapeutics for Gene Silencing Induction of protective effector immunity to prevent pathogenesis caused by the respiratory syncytial virus. Implications on therapy and vaccine design siRNA delivery to the lung: what's new?Inhibition of Respiratory Syncytial Virus Infections With Morpholino Oligomers in Cell Cultures and in Mice Delivery of RNAi Therapeutics to the Airways-From Bench to Bedside Technologies for controlled, local delivery of siRNA Progress toward in vivo use of siRNAs-II Aerosol Delivery of siRNA to the Lungs. Part 1: Rationale for Gene Delivery Systems Respiratory syncytial virus NS1 protein colocalizes with mitochondrial antiviral signaling protein MAVS following infection MicroRNA regulation of human protease genes essential for influenza virus replication Development of pre-clinical models for evaluating the therapeutic potential of candidate siRNA targeting STAT6 Human RGM249-derived small RNAs potentially regulate tumor malignancy Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles Impact of Respiratory Virus Infections in Exacerbation of Acute and Chronic Rhinosinusitis.Drugs in development for influenza.Direct visualization at the single-cell level of siRNA electrotransfer into cancer cells.Hybrid inorganic-organic capsules for efficient intracellular delivery of novel siRNAs against influenza A (H1N1) virus infection Drug delivery-mediated control of RNA immunostimulation First-in-human mutation-targeted siRNA phase Ib trial of an inherited skin disorder.Pharmacologic advances in the treatment and prevention of respiratory syncytial virus.Clinical status of duplex RNA A randomized, double-blind, placebo-controlled study of an RNAi-based therapy directed against respiratory syncytial virus.A status report on RNAi therapeutics.RNA therapeutics: beyond RNA interference and antisense oligonucleotides.The infectious march: the complex interaction between microbes and the immune system in asthma.SiRNA inhibits replication of Langat virus, a member of the tick-borne encephalitis virus complex in organotypic rat brain slices.Nanoscale Diblock copolymer micelles: characterizations and estimation of the effective diffusion coefficients of biomolecules release through cylindrical diffusion model.Development of small RNA delivery systems for lung cancer therapy.Evaluation of dendrimer type bio-reducible polymer as a siRNA delivery carrier for cancer therapy Respiratory syncytial virus, an ongoing medical dilemma: an expert commentary on respiratory syncytial virus prophylactic and therapeutic pharmaceuticals currently in clinical trials Optimizing siRNA delivery to the genital mucosa Current progress of siRNA/shRNA therapeutics in clinical trials.Development of Therapeutic-Grade Small Interfering RNAs by Chemical Engineering.Aerosol Delivery of siRNA to the Lungs. Part 2: Nanocarrier-based Delivery Systems Target mRNA inhibition by oligonucleotide drugs in man.Novel functions for small RNA molecules.Virus meets RNAi. Symposium on antiviral applications of RNA interference.Emerging drugs for respiratory syncytial virus infection.Intrapulmonary delivery of XCL1-targeting small interfering RNA in mice chronically infected with Mycobacterium tuberculosis RNAi Therapeutic Platforms for Lung Diseases.

P2860

Q26786876-9CD16E62-EB0A-4E3C-8017-4648FADE6E66 Q27021304-E67E4DFA-38B1-4230-905D-928FAAD08EF7 Q27022043-673D47C1-7078-4E0A-864A-713F254CFCD6 Q27490424-90E4046E-7344-45DF-87FE-F35FD8410FB2 Q28067306-57631058-1823-4996-8444-71B8D4391FA6 Q28087657-C4A7277C-6089-4B7C-ACD8-FB291753DB03 Q28255877-5B609A40-B705-4112-8B96-EAA1A60390D3 Q28392004-0EAB38BB-2DDB-49C8-9607-65F31330A00B Q28481271-EF5FD995-841C-47A3-98F6-F7CF5A707F24 Q28483683-9ED31D69-A471-42A9-98B1-4F6146209415 Q28540216-5CDEA1F4-61BE-4FAF-80F0-220E6B4D3868 Q28681257-EE5CD224-0507-4AFC-8200-BF62FB1AB6BA Q29615957-A028A344-BB07-4550-9C6D-B192F824044C Q30234896-100070F8-5459-4BD3-B33D-D5C367D54541 Q30391218-3282CC95-7ACD-4B39-9EBA-0F853D628C02 Q30501927-0FC9EA04-730B-4D7B-8C72-AB9DAACF0C67 Q33669734-0500E117-6D36-49DE-AD0C-8302B3762DD1 Q33713938-EDC66F20-9320-427B-B36E-EE677E9AE87F Q33730680-D69031B7-1A19-48BC-B85F-173838C39C6F Q33776507-D31559AF-FD4A-4D67-90E9-7451EBD59AB5 Q33869361-DA9E52A9-280F-4F77-9ED7-B28F02426947 Q33928650-D91776B3-8451-4D44-97E9-7157EF125616 Q34013891-ACF91685-86E6-412C-9A40-8B2DD8A97670 Q34248493-22CB0FE6-1112-40EB-8972-6E316CE64BB2 Q34356430-49A18672-D160-418F-910A-85555C82119C Q34416043-1F23445D-BC46-4AAD-9D14-EAB59334C6CA Q35227017-6674E09D-68E5-4004-AA31-2707DDA0FC43 Q35380932-982B257F-1878-4A2D-93AE-273DB65FF18A Q35691030-6A4AA1FD-C0CE-483B-BB06-C451642EA1C3 Q35761061-FF3EF02A-BD83-4E6A-B6BB-CB5F02CC9E73 Q35766249-263065F7-59B6-4EE8-8C29-BD33D6F1F7E3 Q36071638-CA13C2E5-ACCA-4467-84FF-46ED7D44A71E Q36174842-4913B6E8-C417-40C2-A6F0-CCAE90AFD1D5 Q36341433-237B0AAE-DD54-4B38-9291-37D5A934F946 Q36435109-D46CBAC7-1A4F-4A9B-A242-B3BF495E6314 Q36673371-C436FDCE-66B9-4E33-979D-C111F0C82C29 Q36835313-417CD7CE-D927-4F1E-8BD4-3211F24E88DE Q37250650-106D0E82-404E-4F31-9FBA-79C101A7E49E Q37275462-80D4EAF6-9AD5-4F83-A41B-AE06856FA7CE Q37277373-5F372B29-11C1-4A0B-9C91-0C2014DDEAE3

P2860

Evaluation of the safety, tolerability and pharmacokinetics of ALN-RSV01, a novel RNAi antiviral therapeutic directed against respiratory syncytial virus (RSV).

http://www.wikidata.org/entity/Q45397417

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年学术文章

@wuu

2007年学术文章

@zh

2007年学术文章

@zh-cn

2007年学术文章

@zh-hans

2007年学术文章

@zh-my

2007年学术文章

@zh-sg

2007年學術文章

@yue

2007年學術文章

@zh-hant

name

Evaluation of the safety, tole ...... iratory syncytial virus (RSV).

@en

Evaluation of the safety, tole ...... iratory syncytial virus (RSV).

@nl

type

label

Evaluation of the safety, tole ...... iratory syncytial virus (RSV).

@en

Evaluation of the safety, tole ...... iratory syncytial virus (RSV).

@nl

prefLabel

Evaluation of the safety, tole ...... iratory syncytial virus (RSV).

@en

Evaluation of the safety, tole ...... iratory syncytial virus (RSV).

@nl

P1433

Q45397417-E8E12E84-7991-447C-8A01-A94591A15D6C

P1476

Q45397417-12CA7A37-BFED-45A8-A205-DB471852AA89

P2093

Q45397417-20BD7A00-FBDE-46DA-9818-7946A0187252

Q45397417-35827795-CF3A-4836-8292-DA18B4CAC969

Q45397417-3800D2CF-0730-4CE5-85BC-1AC275D51D44

Q45397417-3CFA331B-F71C-4AEA-AFBF-D215F34C7F35

Q45397417-43431985-7F00-461D-ADAE-61865BC5C845

Q45397417-5689B417-83A5-4F36-99E9-09667055DE5E

Q45397417-57E61354-2BB6-4B92-85E4-FDD81A10E480

Q45397417-5AD57D2C-305E-4112-B726-702DE2939949

Q45397417-5C635A80-03DC-4BB9-9623-C18E8DCE9D15

Q45397417-9ACEEF6C-7730-4708-9417-4D74563B2775

P304

Q45397417-214CB4D6-2EC4-4B75-99E2-A364F843A68C

P31

Q45397417-CB1B6737-D7FB-4496-8908-6096BF037FBD

P356

Q45397417-06580E3F-6C28-4FED-A4AA-E6A122D1C521

P433

Q45397417-DB6A6AB0-EECF-4D72-A952-39D13400F722

P478

Q45397417-05390A17-C2B4-46B9-BA25-204D0A2B0F27

P577

Q45397417-350077BD-E333-46FB-9A43-D0744FFFBDD5

P698

Q45397417-7F47C12D-9970-4309-B55A-5E14F593E66E

P356

J.ANTIVIRAL.2007.11.009

P1433

Antiviral Research

P1476

Evaluation of the safety, tole ...... iratory syncytial virus (RSV).

@en

P2093

Akshay K Vaishnaw

http://www.w3.org/2001/XMLSchema#string

Andre Van Vliet

http://www.w3.org/2001/XMLSchema#string

Iva Toudjarska

http://www.w3.org/2001/XMLSchema#string

Jeffrey E Cehelsky

http://www.w3.org/2001/XMLSchema#string

Jens Harborth

http://www.w3.org/2001/XMLSchema#string

John DeVincenzo

http://www.w3.org/2001/XMLSchema#string

Lubomir Nechev

http://www.w3.org/2001/XMLSchema#string

Rachel Meyers

http://www.w3.org/2001/XMLSchema#string

Rene Alvarez

http://www.w3.org/2001/XMLSchema#string

Sayda Elbashir

http://www.w3.org/2001/XMLSchema#string

P304

225-231

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.ANTIVIRAL.2007.11.009

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

77

http://www.w3.org/2001/XMLSchema#string

P577

2007-12-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18242722

http://www.w3.org/2001/XMLSchema#string